Results 121 to 130 of about 181,126 (162)
Some of the next articles are maybe not open access.
Magyar onkologia, 2019
In the past years, immunotherapy emerged as a novel modality of clinical oncology. The development and introduction of immune checkpoint inhibitors required the development of companion diagnostics, the PD-L1 protein immunohistochemical tests. Unfortunately, almost all checkpoint inhibitors were exclusively validated by a specific PD-L1 in vitro ...
Gábor, Lotz +4 more
openaire +1 more source
In the past years, immunotherapy emerged as a novel modality of clinical oncology. The development and introduction of immune checkpoint inhibitors required the development of companion diagnostics, the PD-L1 protein immunohistochemical tests. Unfortunately, almost all checkpoint inhibitors were exclusively validated by a specific PD-L1 in vitro ...
Gábor, Lotz +4 more
openaire +1 more source
Antineoplastics/programmed-cell-death-1-receptor-antagonists
Reactions Weekly, 2022openaire +1 more source
Programmed-cell-death-1-receptor-antagonists/rivoceranib
Reactions Weekly, 2020openaire +1 more source
Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody
Cancer Control, 2022Bo Hao, Qing Geng
exaly
Programmed cell death-1 receptor antagonists/vemurafenib
Reactions Weekly, 2020openaire +1 more source
Antituberculars/programmed cell death 1 receptor antagonists
Reactions Weekly, 2020openaire +1 more source
Aldesleukin/programmed-cell-death-1-receptor-antagonists
Reactions Weekly, 2019openaire +1 more source
Ipilimumab/urelumab/programmed-cell-death-1-receptor-antagonists
Reactions Weekly, 2021openaire +1 more source